Edgen
Ed 무료 체험
Ryan Patel - Healthcare & Life Sciences Analyst at Edgen

Ryan Patel

Healthcare & Life Sciences Analyst

Drug pipelines, FDA catalysts, and biotech valuation. Came from equity research at Jefferies covering mid-cap pharma. His analysis tends to be contrarian — he'll downgrade a consensus favorite if the Phase 3 data doesn't hold up to scrutiny.
Latest
AbbVie 매수 등급, 목표가 $250. FY2025 매출 $61.16B(+10.6%), Skyrizi+Rinvoq $27B 연간 런레이트, FCF $17.8B, 배당 귀족. Edgen에서 전체 분석을 확인하세요.

AbbVie 주식 분석: Skyrizi와 Rinvoq가 제약 투자 논리를 재정의하다 | Edgen

The global pharmaceutical industry in 2026 is navigating a structural transformation driven by three converging forces: the largest patent cliff cycle in the sector's history, the implementation of the Inflation Reduction Act's drug price negotiation provisions, and a widening bifurcation between companies with genuine innovation engines and those reliant on mature, commoditizing portfolios. Between 2023 and 2030, branded drugs representing over $250 billion in peak annual revenue will lose patent protection, exposing companies to biosimilar and generic competition that typically erodes 60-80% of branded revenue within three to five years of exclusivity loss. AbbVie's Humira, which peaked at $21.2 billion in annual sales in 2022 as the world's best-selling drug, was the poster child for this risk. The drug's U.S. biosimilar entry in January 2023 triggered an immediate and sustained revenue decline — Humira revenue fell to approximately $14.4 billion in FY2023, then approximately $10.2
Ryan Patel
·
Apr 20 2026

투자, 드디어 혼자 안 해도 돼요.

Ed 무료 체험. 신용카드 필요 없고, 약정도 없어요.
Ed 무료 체험